Dronabinol - INSYS Therapeutics

Drug Profile

Dronabinol - INSYS Therapeutics

Alternative Names: 9-Tetrahydrocannabinol oral solution - INSYS Therapeutics; 9-THC oral solution - INSYS Therapeutics; Syndros

Latest Information Update: 30 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSYS Therapeutics, Inc
  • Class Antiemetics; Appetite stimulants; Cannabinoids; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anorexia; Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 25 Apr 2018 The US FDA approves IND application for dronabinol inhalation in Chemotherapy-induced nausea and vomiting and Anorexia (associated with weight loss in AIDS patients)
  • 25 Apr 2018 INSYS plans clinical trials for dronabinol inhalation in Chemotherapy-induced nausea and vomiting, and anorexia (associated with weight loss in patients with AIDS)
  • 18 Apr 2018 INSYS Therapeutics announces intention to submit IND to the US FDA for dronabinol inhalation for Anorexia in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top